Monday, August 31, 2026

Insurers pulled Medicare Advantage plan offerings for 2.6 million enrollees, a massive year-over-year churn event that reflects a strategic retreat from unprofitable markets. The annual election period for 2027 begins in October. For practices with high MA patient volume, this signals a wave of coverage changes and potential payer mix shifts. Billing teams should prepare for a surge in patient eligibility checks and possible re-credentialing requests. Contact your MA-heavy patients now to confirm their 2027 plan selection and update your payer grid before January 1.

New data shows insurers on the federal and state marketplaces deny nearly 20% of claims, forcing patients to pay hundreds monthly out-of-pocket. This denial rate is significantly higher than group commercial plans. For practices that see a large number of ACA marketplace patients, this translates to increased administrative burden and slower cash flow. Monitor your 2026 denial reports for marketplace plans; if the 20% rate holds in your data, consider tightening point-of-service collection policies and accelerating patient responsibility estimates before service.

CMS's pilot program to lower GLP-1 drug costs for Medicare beneficiaries includes strict clinical criteria that exclude some patients with obesity-related complications. The program, designed as a test of value-based pricing, requires a specific BMI threshold and the presence of at least one cardiovascular condition, leaving out patients with conditions like osteoarthritis or sleep apnea. This creates a coverage cliff for practices managing complex patients and illustrates the operational friction of CMS's incremental approach to covering weight-loss drugs.

A growing number of U.S. employers plan to exclude GLP-1 agonists for weight loss from their 2027 benefit plans, citing unsustainable cost trends. This follows similar moves announced earlier in the year. For practices, this means increased prior authorization denials and patient affordability conversations for drugs like Wegovy and Zepbound starting January 1. Update your patient financial counseling scripts and eligibility verification workflows now to include specific questions about GLP-1 coverage under the patient's 2027 plan.